Sort   by:  
 Page size 
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed DrugMap, an atlas o...
ORGANISM(S): Homo sapiens (Human) 
2024-04-23 | PXD047840 | Pride
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
The nucleus controls cell growth and reproduction by well-orchestrated interactions between nuclear proteins and chromatin. Mutations that result in the dysregulation of these chromatin-associated proteins are known to lead to the onset of numerous diseases. Many of these nuclear proteins have remai...
ORGANISM(S): Homo sapiens (Human) 
2024-01-24 | PXD043732 | Pride
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability (ChIP-Seq)
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability (RNA-Seq)
Covalent chemistry coupled with activity-based protein profiling (ABPP) offers a versatile approach for small-molecule ligand discovery in native biological contexts. The covalent ligandability maps generated by ABPP that target cysteine have frequently leveraged the acrylamide as a reactive group d...
ORGANISM(S): Homo sapiens (Human) 
2026-05-20 | PXD074619 | Pride
isoTOP-ABPP performed for a small library of cysteine-reactive compounds to assess cysteine ligandability of viral and host proteins towards these compounds.
ORGANISM(S): Homo sapiens (Human) 
2024-10-24 | PXD046278 | Pride
Chemical probes are lacking for most human proteins. Covalent chemistry represents an attractive strategy for expanding the ligandability of the proteome, and chemical proteomics has revealed numerous electrophile-reactive cysteines on diverse proteins. Determining which of these covalent binding ev...
ORGANISM(S): Homo sapiens (Human) 
2023-09-06 | PXD038239 | Pride
Sort   by:  
 Page size